1. Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II 
Menno V. Huisman, MD, Kenneth J. Rothman, DrPH, Miney Paquette, MSc, Christine Teutsch, MD, Hans Christoph Diener, MD, Sergio J. Dubner, MD, Jonathan L. Halperin, MD, Changsheng Ma, MD, Kristina Zint, MD, Amelie Elsaesser, MD, Dorothee B. Bartels, MD, Gregory Y.H. Lip, MD 
The American Journal of Medicine 
Volume 128, Issue 12, Pages e1 (December 2015)
DOI: /j.amjmed
Copyright © 2015 Elsevier Inc. Terms and Conditions

2. Figure 1
Definition of geographical regions and country participation in GLORIA-AF.
The American Journal of Medicine  , e1DOI: ( /j.amjmed )
Copyright © 2015 Elsevier Inc. Terms and Conditions

3. Figure 2
Atrial fibrillation types and symptom categories (all regions).
The American Journal of Medicine  , e1DOI: ( /j.amjmed )
Copyright © 2015 Elsevier Inc. Terms and Conditions

4. Figure 3
Antithrombotic treatment at baseline overall and by stroke risk (all regions). ASA = acetylsalicylic acid; VKA = vitamin K antagonists.
The American Journal of Medicine  , e1DOI: ( /j.amjmed )
Copyright © 2015 Elsevier Inc. Terms and Conditions

5. Figure 4
Antithrombotic treatment at baseline by region. ASA = acetylsalicylic acid; VKA = vitamin K antagonists.
The American Journal of Medicine  , e1DOI: ( /j.amjmed )
Copyright © 2015 Elsevier Inc. Terms and Conditions

6. Figure 5
Antithrombotic treatment at baseline by stroke risk and region.
The American Journal of Medicine  , e1DOI: ( /j.amjmed )
Copyright © 2015 Elsevier Inc. Terms and Conditions